Company / R&D Expense
ALNYLAM PHARMACEUTICALS, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.3B
FY2025
5-year range
$654.8M / $1.3B
FY2021-FY2025
Trend
+17.2%
vs FY2024
Sector context
#15 of 210
Health Care
What the data says
Among 210 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the top 7% for r&d expense. R&D Expense has increased for 3 consecutive years, from $655M in FY2022 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +21.2%. Top quartile in the Health Care sector.
Improved from $1.0B to $1.3B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +26.3%
- 5-Year CAGR
- +21.2%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 210This company $1.3B Sector average $644.0M
▼
+104.9% above sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +21.2%, indicating consistent growth.
- In FY2025, r&d expense increased 17.2% year-over-year.
- Ranks #15 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +17.2% |
| FY2024 | $1.1B | +12.1% |
| FY2023 | $1.0B | +53.4% |
| FY2022 | $654.8M | -0.0% |
| FY2021 | $655.1M | +29.6% |
| FY2020 | $505.4M | +29.4% |
| FY2019 | $390.6M | +2.2% |
| FY2018 | $382.4M | -2.1% |
| FY2017 | $390.6M | +2.2% |
| FY2016 | $382.4M | +38.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026